Intellia Therapeutics, Inc.
NTLA- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001652130
In the last 90 days, Intellia Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 329 institutions reported holding it in 13F filings for Q2 2026, worth $2.43B in total; ARK Invest is the only superinvestor holding it.
13F holders, Q2 2023
Institutional positions in Intellia Therapeutics, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 292
- +1 vs. Q1 2023
- Shares held
- 78.3M
- −445.3K (−0.6%) vs. Q1 2023
- Total value
- $3.19B
- +$261.5M (+8.9%) vs. Q1 2023
- New holders
- 35
- 108 more added
- Sold out
- 34
- 73 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NTLA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 329 | $2.43B |
| Q1 2026 | 306 | $1.41B |
| Q4 2025 | 295 | $938.9M |
| Q3 2025 | 284 | $1.80B |
| Q2 2025 | 283 | $933.8M |
| Q1 2025 | 296 | $720.3M |
| Q4 2024 | 295 | $1.16B |
| Q3 2024 | 284 | $1.92B |
| Q2 2024 | 291 | $2.02B |
| Q1 2024 | 284 | $2.51B |
| Q4 2023 | 293 | $2.60B |
| Q3 2023 | 286 | $2.53B |
| Q2 2023 | 292 | $3.19B |
| Q1 2023 | 291 | $2.93B |
| Q4 2022 | 304 | $2.72B |
| Q3 2022 | 321 | $3.81B |
| Q2 2022 | 301 | $3.44B |
| Q1 2022 | 348 | $4.71B |
| Q4 2021 | 372 | $7.60B |
| Q3 2021 | 366 | $8.34B |
| Q2 2021 | 337 | $10.0B |
| Q1 2021 | 261 | $5.07B |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Intellia Therapeutics, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Algert Global LLC | 0 | $0 | 0.00% | −23,610−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −21,571−100.0% | Sold out |
| Canada Pension Plan Investment Board | 0 | $0 | 0.00% | −20,100−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −16,554−100.0% | Sold out |
| Banque Pictet & Cie SA | 0 | $0 | 0.00% | −15,878−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −13,258−100.0% | Sold out |
| Brookfield Asset Management Inc. | 0 | $0 | 0.00% | −12,831−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −11,119−100.0% | Sold out |
| Hongkou Capital LP | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −8,200−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −7,714−100.0% | Sold out |
| Allianz Asset Management GmbH | 0 | $0 | 0.00% | −7,400−100.0% | Sold out |
| Atria Wealth Solutions, Inc. | 0 | $0 | 0.00% | −7,251−100.0% | Sold out |
| First Republic Investment Management, Inc. | 0 | $0 | 0.00% | −6,235−100.0% | Sold out |
| Ionic Capital Management LLC | 0 | $0 | 0.00% | −5,685−100.0% | Sold out |
| Natixis | 0 | $0 | 0.00% | −3,668−100.0% | Sold out |
| Values First Advisors, Inc. | 0 | $0 | 0.00% | −1,701−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −1,261−100.0% | Sold out |
| Belpointe Asset Management LLC | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| Ellevest, Inc. | 0 | $0 | 0.00% | −279−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −191−100.0% | Sold out |
| Front Row Advisors LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Toth Financial Advisory Corp | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Ronald Blue Trust, Inc. | 0 | $0 | 0.00% | −23−100.0% | Sold out |
| Financial Synergies Wealth Advisors, Inc. | 0 | $0 | 0.00% | −25−100.0% | Sold out |
| Ancora Advisors, LLC | 0 | $0 | 0.00% | −15−100.0% | Sold out |